Spike Postdoctoral Research Papers on International Frontier Journals
Release time:
2022-06-01
Recently, good news came from the postdoctoral workstation of Jianfeng Pharmaceutical. Under the guidance of workstation mentor Jiang Xiaomeng, associate researcher Yang Xiaoxiao has made new progress in the treatment of alcoholic liver disease. The relevant research results "Roxadustat , A hypoxia-inducible factor 1a activator, attenuates both long- and short-term alcohol induced alcoholic liver disease was published in the internationally renowned academic journal" Frontiers in Pharmacology . This journal is a frontier journal in the field of international pharmacy, mainly publishing academic papers and information on basic and clinical pharmacology, medicinal chemistry, pharmacology and toxicology.
Alcoholic liver disease is one of the main types of liver disease in the world. Its pathogenesis includes the initial alcoholic fatty liver, which further evolves into alcoholic steatohepatitis, and even liver fibrosis and cirrhosis. It may deteriorate into liver cancer, and the pathogenesis is more complex, which has always been a hot topic in academic research. Previous academic research on alcoholic liver disease mainly focused on lipid metabolism disorders, alcohol-induced inflammatory infiltration, oxidative stress in liver cells, and intestinal microbial disorders. The research results of Yang Xiaoxiao and others focused on the new role of the chronic kidney disease anemia treatment drug roxaldostat in alcoholic liver disease. The therapeutic effect of roxaldostat was explored by constructing acute and chronic alcoholic liver disease models, and combined with cell experiments to verify the therapeutic effect. The results show that alcohol can cause lipid metabolism disorders, and also cause inflammation, oxidative stress and other adverse effects in the liver. Roxastat increases fatty acid oxidation by inhibiting the expression of lipid synthesis genes SREBP1c , ChREBP , FASN , ACC1 , DGAT1 , and promoting PPAR ; roxalustat can also reduce the accumulation of macrophages and the release of proinflammatory cytokines to improve the inflammatory process; roxalustat reduces the expression of CYP2E1 and promotes superoxide dismutase SOD1 , which can alleviate the oxidative stress caused by alcohol. The above studies show that roxalustat can be used as a potential treatment for alcoholic liver disease.
The research was supported by the China Postdoctoral Science Foundation and the Zhejiang Provincial Postdoctoral Program. Gao Yongyao and Yang Daigang, graduate students of Hefei University of Technology, are the co-first authors, and Yang Xiaoxiao, associate researcher, is the corresponding author.
More information
Peak re-listed China's top 100 cement production capacity Daye peak won the "smart factory leader"
On July 11-12, the 2022 China Cement Industry Summit and TOP100 Award Ceremony organized by China Cement Network, an authoritative media of China's cement industry, was held in Hangzhou. Jianfeng Group once again ranked among the top 100 cement clinker production capacity in China.
2022
08-04
On the afternoon of July 12, the party Committee of the group company held a special meeting attended by party Committee members, senior and middle-level management backbones, heads of grass-roots party organizations and all party members of the group headquarters to learn and convey the spirit of the 15th party congress of the communist party of China in Zhejiang province.
2022
07-24
On the morning of July 1, more than 40 members of the group's party committee, party members of various branches of the group headquarters, and party members of subordinate enterprise branches went to the Shuanglong Hydropower Station, the Red Education Base of Jinhua City, to receive party spirit and revolutionary tradition education.
2022
07-14
Vocational skill level identification examination!
On June 16 and 18, the theoretical and practical examinations for the determination of professional skill level in the peak pharmaceutical sector were held successively in Jinxi pharmaceutical factory. The independent identification of vocational skill level includes three occupations (types of work): pharmaceutical preparation worker, chemical inspector and organic synthesis worker, basically covering the main posts in the pharmaceutical sector, with a total of 125 employees signing up for the identification.
2022
06-21
On June 16, the Jianfeng Pharmaceutical Quality Research and Development Party Branch and the Jinhua Vocational Skills Management Service Center Party Branch held a signing ceremony in Jinxi Factory to establish a party building alliance.
2022
06-21
Jinhua Mayor Xing Zhihong to Peak Research
On the afternoon of June 1, Jinhua Mayor Xing Zhihong, Wucheng District Party Committee Secretary Gao Feng, District Mayor Hu Yuxian, and heads of the Municipal Economic and Information Bureau, Development and Reform Bureau and other departments went to the group headquarters to discuss and exchange with the leaders of the group company to understand the development of the enterprise. Solicit opinions and suggestions from enterprises on government work. After understanding the current business situation of the peak, Xing Zhihong pointed out that focus, follow the right path, frontier, steady, is the peak to long-term prosperity of the magic weapon, must continue to adhere.
2022
06-13
Contact Us
No. 88 Wujiang East Road, Jinhua City, Zhejiang Province, China
Tel: +86-579-82326868
Fax : +86-579-82324666
©2023 Zhejiang Jianfeng Group Co., Ltd. Powered by: www.300.cn SEO Business License
SAF Coolest v1.2 设置面板 SHJSS-AHDB-FSSQE-ZSW
无数据提示
Sorry, the current column has no content !
You can view other columns or return to Home Page